Scenarios that move CVS
CVS Health Corporation Common Stock
Scenarios that move CVS: 25 analyses, 17 positive, 8 negative.
- · Opus Genetics receives FDA approval for presbyopia eye drop — ▲ · impact +15 · confidence medium · horizon quarters
- · EU approves Kimberly-Clark's $40 billion Kenvue acquisition — ▼ · impact -15 · confidence low · horizon quarters
- · Mirum's Livmarli meets Phase III goal in ultra-rare liver diseases — ▲ · impact +8 · confidence low · horizon quarters
- · J&J beats Q3 earnings estimates, misses sales and raises outlook — ▼ · impact -22 · confidence low · horizon quarters
- · UnitedHealth tops estimates, raises profit outlook despite high medical costs — ▲ · impact +56 · confidence medium · horizon weeks
- · Viking Therapeutics advances oral obesity drug to Phase III — ▲ · impact +20 · confidence low · horizon quarters
- · Hims & Hers faces securities fraud class action after FTC lawsuit — ▲ · impact +18 · confidence low · horizon quarters
- · Bavarian Nordic raises 2026 outlook after strong Travel Health results — ▲ · impact +14 · confidence low · horizon quarters
- · Centene narrows Medicare Advantage footprint as costs remain elevated — ▲ · impact +40 · confidence medium · horizon quarters
- · ◇ What if… Republicans win Kansas Senate race in 2026 — ▼ · impact -30 · confidence low · horizon quarters
- · Liquidia stock plunges 57% after UTHR patent setback — ▲ · impact +8 · confidence low · horizon quarters
- · United Therapeutics stock rises 12.6% in trading — ▲ · impact +13 · confidence low · horizon quarters
- · Zealand Pharma reports positive survodutide Phase III weight loss results — ▲ · impact +25 · confidence low · horizon quarters
- · Novo Nordisk's Ozempic outperforms Lilly's Mounjaro on cardiovascular risk — ▲ · impact +38 · confidence low · horizon quarters
- · Ulta Beauty raises 2026 outlook as e-commerce momentum accelerates — ▼ · impact -22 · confidence medium · horizon weeks
- · Lilly reports strong weight loss results for new drug — ▲ · impact +30 · confidence low · horizon quarters
- · DBV Technologies files FDA BLA for VIASKIN Peanut patch — ▲ · impact +7 · confidence low · horizon quarters
- · ◇ What if… Oral GLP-1 drugs replace injectable treatments — ▲ · impact +34 · confidence medium · horizon quarters
- · ◇ What if… Samuel Alito announces retirement by December 31, 2026 — ▼ · impact -15 · confidence low · horizon quarters
- · FDA approves Isembyld for spinal muscular atrophy treatment — ▲ · impact +25 · confidence low · horizon weeks
- · ◇ What if… Democrats win control of the House after 2026 midterm elections — ▼ · impact -42 · confidence low · horizon quarters
- · OPEC Announces Surprise 2M Barrel Increase — ▲ · confidence low
- · ◇ What if… Major Cyberattack Disrupts Largest US Health Insurance Claims Processors Nationwide — ▼ · confidence medium
- · ◇ What if… Major Cyberattack Takes Down Two Largest US Health Insurance Claims Processors — ▼ · confidence medium
- · Eli Lilly Weight Loss Pill Shows Better Results Than Injectable Competitors In Phase 3 Trial — ▲ · confidence low